SCI时时刷

search
+
Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review
Human Inborn Errors of Immunity in Pyoderma Gangrenosum: A Systematic Review
Pyoderma gangrenosum (PG) is a rare ulcerative neutrophilic dermatosis that can be associated with primary immunodeficienc...
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial
Efficacy and Safety of Brodalumab, an Anti-interleukin-17 Receptor A Monoclonal Antibody, for Palmoplantar Pustulosis: 16-Week Results of a Randomized Clinical Trial
Palmoplantar pustulosis (PPP), a refractory skin disease characterized by repeated eruptions of sterile pustules and vesic...
Lichen Planus: What is New in Diagnosis and Treatment?
Lichen Planus: What is New in Diagnosis and Treatment?
Lichen planus (LP), an idiopathic, multifaceted chronic inflammatory disease with a heterogeneous clinical presentation, a...
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
Sequencing of Targeted Therapy in Psoriasis: Does it Matter?
With the continued development of biologics for the treatment of psoriasis, some patients have achieved optimal control, b...
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data
Association Between Biologic Exposure and the Risk of Depression in Patients with Psoriasis: A Retrospective Analysis of Large US Administrative Claims Data
Funding AbbVie funded the study. AbbVie participated in the study d...
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
The Current State of Systemic Therapy of Metastatic Uveal Melanoma
Uveal melanoma (UM) is genetically a distinct tumor compared to cutaneous melanoma (CM), and due to its low mutational bur...
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure
Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure
Abrocitinib, an oral, once-daily, Janus kinase 1-selective inhibitor, is efficacious in moderate-to-severe atopic dermatit...
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
Evaluation of the Tolerability of Hedgehog Pathway Inhibitors in the Treatment of Advanced Basal Cell Carcinoma: A Narrative Review of Treatment Strategies
Hedgehog pathway inhibitors (HHIs) have broadened the treatment options available for patients with advanced basal cell ca...
Adherence to Hidradenitis Suppurativa Treatment
Adherence to Hidradenitis Suppurativa Treatment
Hidradenitis suppurativa (HS) is a chronic, debilitating skin condition that requires multimodal treatment. Adherence rema...
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment
Switching to Interleukin-23 Inhibitors After Ineffectiveness of Ustekinumab: Evaluating Real-World Outcomes in Psoriasis Treatment
Funding This study was supported by The University Medical Center S...
Managing the Patient with Psoriasis and Metabolic Comorbidities
Managing the Patient with Psoriasis and Metabolic Comorbidities
Epidemiological data demonstrate strong associations between psoriasis and metabolic comorbidities, including obesity, hyp...
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review
Management and Long-Term Outcomes of Drug Reaction with Eosinophilia and Systemic Symptoms (DReSS) in Children: A Scoping Review
Drug reaction with eosinophilia and systemic symptoms (DReSS) is known to cause mortality and long-term sequelae in the pe...
Approach to the Atypical Wound
Approach to the Atypical Wound
The heterogeneity of atypical wounds can present diagnostic and therapeutic challenges; however, as the prevalence of atyp...
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Dupilumab Safety and Efficacy up to 1 Year in Children Aged 6 Months to 5 Years with Atopic Dermatitis: Results from a Phase 3 Open-Label Extension Study
Pediatric patients with moderate-to-severe atopic dermatitis (AD) often experience a high disease burden and have a high r...
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
Efficacy, Safety, and Long-Term Disease Control of Ruxolitinib Cream Among Adolescents with Atopic Dermatitis: Pooled Results from Two Randomized Phase 3 Studies
Atopic dermatitis (AD), a highly pruritic, inflammatory skin disease, affects approximately 7% of adolescents globally. A ...
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates
Merkel cell carcinoma (MCC) is a rare skin cancer characterized by neuroendocrine differentiation. Its carcinogenesis is b...
Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis
Ultrasound Surveillance in Melanoma Management: Bridging Diagnostic Promise with Real-World Adherence: A Systematic Review and Meta-Analysis
Ultrasound surveillance has become the new standard of care in stage III melanoma after the 2017 Multicenter Selective Lym...
Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses
Secondary Bacterial Infections in Patients with Atopic Dermatitis or Other Common Dermatoses
Secondary bacterial infections of common dermatoses such as atopic dermatitis, ectoparasitosis, and varicella zoster virus...
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2)
Atopic dermatitis is a chronic inflammatory disease characterized by increased itch, skin pain, poor sleep quality, and ot...
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada
Tree-Based Machine Learning to Identify Predictors of Psoriasis Incidence at the Neighborhood Level: A Populational Study from Quebec, Canada
Psoriasis is a major global health burden affecting ~ 60 million people worldwide. Existing studies on psoriasis focused o...
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis
Small-Molecule Inhibitors and Biologics for Palmoplantar Psoriasis and Palmoplantar Pustulosis: A Systematic Review and Network Meta-Analysis
The comparative efficacy of biologics and small-molecule inhibitors in treating palmoplantar psoriasis (PP) and palmoplant...
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma
Rapidly Evolving Pre- and Post-surgical Systemic Treatment of Melanoma
With the development of effective BRAF-targeted and immune-checkpoint immunotherapies for metastatic melanoma, clinical tr...
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
The Impact of Dermatologic Adverse Events on the Quality of Life of Oncology Patients: A Review of the Literature
Dermatologic adverse events resulting from oncologic therapy are common and negatively impact patients’ quality of l...
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
Therapeutic Strategies in BRAF V600 Wild-Type Cutaneous Melanoma
There have been many recent advances in melanoma therapy. While 50% of melanomas have a BRAF mutation and are a target for...
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
The ALLEGRO phase 2a and 2b/3 studies demonstrated that ritlecitinib, an oral JAK3/TEC family kinase inhibitor, is efficac...
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
Treatment of Psoriasis Patients with Latent Tuberculosis Using IL-17 and IL-23 Inhibitors: A Retrospective, Multinational, Multicentre Study
Tuberculosis has a major global impact. Immunocompetent hosts usually control this disease, resulting in an asymptomatic l...
The Skin Microbiome and its Significance for Dermatologists
The Skin Microbiome and its Significance for Dermatologists
The skin is a physical and immunological barrier to the external environment. Its large surface area is colonized by diver...
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
OX40 in the Pathogenesis of Atopic Dermatitis—A New Therapeutic Target
Atopic dermatitis (AD) is a chronic, heterogeneous, inflammatory disease characterized by skin lesions, pruritus, and pain...
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year
Ruxolitinib cream is the first topical Janus kinase (JAK) inhibitor approved in the United States (US) for the treatment o...
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Therapeutic options for people with moderate or severe atopic dermatitis refractory to topical therapy have rapidly expand...
阅读更多
format_indent_increase